Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

• Status: Not yet recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The study purpose is to evaluate the safety of T4090.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Laboratoires Thea

Criteria

Inclusion Criteria:

• Informed consent dated and signed.

• Both eyes diagnosed open-angle glaucoma or ocular hypertension

Exclusion Criteria:

• History of trauma, infection, clinically significant inflammation within the previous 6 months

• Known or suspected hypersensitivity to one of the components of the Investigational Medicinal Product(s)

• Pregnancy or breast-feeding